Read More Pharma Industry News Tarsus Pharmaceuticals (NASDAQ: TARS) to add Alkeus in $800m eye pipeline deal Tarsus lines up an $800m Alkeus deal and a $125m PIPE to enter Stargardt disease, but a 2029 readout and Belite Bio's lead still gate the retina thesis. bySrinathAugust 10, 2026